
X
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trial
https://pharmaphorum.com/news/ucbs-il-17-latecomer-bimekizumab-beats-cosentyx-in-psoriasis-trial/
Craig Morgan outlines why comparator trials are useful and provides points to consider to ensure the best outcome.